Geratherm Medical AG: Voluntary delisting offer by JotWe GmbH published
Geratherm Medical AG
Voluntary delisting offer by JotWe GmbH published
- Offer price EUR 8.50 per share
Geratal, May 11, 2022. Today JotWe GmbH, based in Steinbach am Wald, has today published an offer document for the voluntary public takeover bid for all shares in Geratherm Medical AG, Geratal (ISIN: DE0005495626) and sent it to the Management of Geratherm Medical AG. JotWe GmbH offers the shareholders of Geratherm Medical AG EUR 8.50 per share in cash. The offer document can be found at https://www.jotwebe-offer.de .
The acceptance period begins today, May 11, 2022, and is expected to run until June 8, 2022, unless it is extended in accordance with the statutory provisions of the German Securities Acquisition and Takeover Act (WpÜG). If such a deadline extension occurs, it will be published immediately. The additional acceptance period is expected to begin on June 14, 2022 and end on June 27, 2022. A written declaration to the respective custodian bank is required to accept the offer.
The Management Board and Supervisory Board of Geratherm Medical AG will examine the offer carefully and publish a statement in accordance with Section 27 WpÜG within two weeks. As already announced in the ad hoc announcement of April 13, 2022, the Management Board and the Supervisory Board generally welcome the offer and, once the offer has been completed, are aiming for a downlisting with a future listing in the Scale segment - the stock market segment for medium-sized companies - on the Frankfurt Stock Exchange. The joint statement will be published on the company's website at https://geratherm.com under Investor Relations section.
The Management Board
Geratherm Medical AG
Geratherm Medical is an internationally oriented medical technology company with the business areas Healthcare Diagnostics, Medical Warming Systems, Cardio/Stroke and Respiratory. Our roots lie in medical temperature measurement. In this field we offer a wide range of products, most of which have unique selling points. We provide our customers/patients with high-quality products ranging from clinical thermometers to MRI-capable incubators for newborns. In the Cardio segment, we focus on product developments for the detection of atrial fibrillation for stroke prevention. The Respiratory segment develops and sells products for measuring pulmonary function. Geratherm has patent-protected basic technologies in all key business areas. We see ourselves as a research-based medical technology company with a clear focus on medical diagnostic products for the generation of vital data. Geratherm shares have been admitted to official trading on the Frankfurt Stock Exchange - in the so-called primary standard - since 2000. Furthermore, Geratherm Medical is represented in the so-called German Entrepreneurial Index and in the German Healthcare Index.
Dr. Gert Frank
End of Media Release
Issuer: Geratherm Medical AG
Key word(s): Enterprise
11.05.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Company:||Geratherm Medical AG|
|Phone:||+49 (0)36205 98-0|
|Fax:||+49 (0)36205 98-1 15|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1349799|
|End of News||DGAP Media|